Heterotopic Ossification Medication
- Author: John Speed, MBBS; Chief Editor: Consuelo T Lorenzo, MD more...
Today, the medical treatment of HO is directed at early HO. In the later stages of the development of mature bone, medical treatment is ineffective. Etidronate (Didronel) is the only available medication for the treatment of HO after SCI.[19, 34] Treatment with NSAIDs may be required initially, until the resolution of inflammation and the normalization of CRP levels.
Nonsteroidal anti-inflammatory agents
Presumed to have direct and indirect effects on the formation of HO. Direct effect refers to the inhibition of the differentiation of mesenchymal cells into osteogenic cells, and indirect effect refers to the inhibition of posttraumatic bone remodeling by suppression of the prostaglandin-mediated inflammatory response.
Known to inhibit synthesis of prostaglandins.
The bisphosphonate group of compounds has properties similar to naturally occurring pyrophosphate, which may be a regulator of calcification. Etidronate disodium is the most extensively studied of this class of drugs for the treatment of HO. Etidronate acts by (1) inhibiting precipitation of calcium phosphate from unsaturated solutions, (2) delaying aggregation of apatite crystals into layers, and (3) blocking conversion of calcium phosphate into hydroxyapatite. Apparently, predisposition to the inflammatory process and mineralization decreases with time, although it is not understood why. This phenomenon may be why there is no massive rebound bone formation after cessation of etidronate. Thus, the effectiveness of etidronate depends entirely on when and how long it is given, and the drug does not affect HO that has already formed.
Reduces bone formation and does not alter renal tubular reabsorption of calcium. The effects of etidronate increase as the dose increases. Agent does not appear to affect fracture healing.
Kaplan FS, Xu M, Glaser DL, et al. Early diagnosis of fibrodysplasia ossificans progressiva. Pediatrics. 2008 May. 121(5):e1295-300. [Medline].
Shafer DM, Bay C, Caruso DM, et al. The use of eidronate disodium in the prevention of heterotopic ossification in burn patients. Burns. 2008 May. 34(3):355-60. [Medline].
Peterson JR, De La Rosa S, Sun H, Eboda O, Cilwa KE, Donneys A, et al. Burn Injury Enhances Bone Formation in Heterotopic Ossification Model. Ann Surg. 2013 May 12. [Medline].
Subbarao JV, Garrison SJ. Heterotopic ossification: diagnosis and management, current concepts and controversies. J Spinal Cord Med. 1999 Winter. 22(4):273-83. [Medline].
Pathophysiology of heterotopic ossification. Orthop Nurs. 2013 May-Jun. 32(3):178-9. [Medline].
Zychowicz ME. Pathophysiology of heterotopic ossification. Orthop Nurs. 2013 May-Jun. 32(3):173-7. [Medline].
Rossier AB, Bussat P, Infante F, et al. Current facts of para-osteo-arthropathy (POA). Paraplegia. 1973 May. 11(1):38-78. [Medline].
Wilson KW, Dickens JF, Heckert R, Tintle SM, Keeling JJ, Andersen RC, et al. Heterotopic ossification resection after open periarticular combat-related elbow fractures. J Surg Orthop Adv. 2013 Spring. 22(1):30-5. [Medline].
Bodley R, Jamous A, Short D. Ultrasound in the early diagnosis of heterotopic ossification in patients with spinal injuries. Paraplegia. 1993 Aug. 31(8):500-6. [Medline].
Snoecx M, De Muynck M, Van Laere M. Association between muscle trauma and heterotopic ossification in spinal cord injured patients: reflections on their causal relationship and the diagnostic value of ultrasonography. Paraplegia. 1995 Aug. 33(8):464-8. [Medline].
Hassard GH. Heterotopic bone formation about the hip and unilateral decubitus ulcers in spinal cord injury. Arch Phys Med Rehabil. 1975 Aug. 56(8):355-8. [Medline].
Downing MR, Knox D, Gibson P, et al. Impact of trochanteric heterotopic ossification on measurement of femoral bone density following cemented total hip replacement. J Orthop Res. 2008 Apr 10. [Medline].
Macfarlane RJ, Ng BH, Gamie Z, et al. Pharmacological treatment of heterotopic ossification following hip and acetabular surgery. Expert Opin Pharmacother. 2008 Apr. 9(5):767-86. [Medline].
Foruria AM, Augustin S, Morrey BF, Sánchez-Sotelo J. Heterotopic ossification after surgery for fractures and fracture-dislocations involving the proximal aspect of the radius or ulna. J Bone Joint Surg Am. 2013 May 15. 95(10):e661-7. [Medline].
Garland DE, Blum CE, Waters RL. Periarticular heterotopic ossification in head-injured adults. Incidence and location. J Bone Joint Surg Am. 1980 Oct. 62(7):1143-6. [Medline].
Singh RS, Craig MC, Katholi CR, et al. The predictive value of creatine phosphokinase and alkaline phosphatase in identification of heterotopic ossification in patients after spinal cord injury. Arch Phys Med Rehabil. 2003 Nov. 84(11):1584-8. [Medline].
Sherman AL, Williams J, Patrick L, et al. The value of serum creatine kinase in early diagnosis of heterotopic ossification. J Spinal Cord Med. 2003. 26(3):227-30. [Medline].
Estrores IM, Harrington A, Banovac K. C-reactive protein and erythrocyte sedimentation rate in patients with heterotopic ossification after spinal cord injury. J Spinal Cord Med. 2004. 27(5):434-7. [Medline].
Banovac K. The effect of etidronate on late development of heterotopic ossification after spinal cord injury. J Spinal Cord Med. 2000 Spring. 23(1):40-4. [Medline].
Freed JH, Hahn H, Menter R, et al. The use of the three-phase bone scan in the early diagnosis of heterotopic ossification (HO) and in the evaluation of Didronel therapy. Paraplegia. 1982 Aug. 20(4):208-16. [Medline].
Bachman DR, Kamaci S, Thaveepunsan S, et al. Preoperative nerve imaging using computed tomography in patients with heterotopic ossification of the elbow. J Shoulder Elbow Surg. 2015 Mar 11. [Medline].
Lindeque BG, Fleming ME, Waterman SS, Lewandowski LR, Chi BB. Use of 3-dimensional stereolithographic polymer models for heterotopic ossification surgical excision. Orthopedics. 2013 Apr 1. 36(4):282-6. [Medline].
Bradleigh LH, Perkash A, Linder SH, et al. Deep venous thrombosis associated with heterotopic ossification. Arch Phys Med Rehabil. 1992 Mar. 73(3):293-4. [Medline].
Varghese G, Williams K, Desmet A, et al. Nonarticular complication of heterotopic ossification: a clinical review. Arch Phys Med Rehabil. 1991 Nov. 72(12):1009-13. [Medline].
Banovac K, Williams JM, Patrick LD, et al. Prevention of heterotopic ossification after spinal cord injury with indomethacin. Spinal Cord. 2001 Jul. 39(7):370-4. [Medline].
Banovac K, Williams JM, Patrick LD, et al. Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib). Spinal Cord. 2004 Dec. 42(12):707-10. [Medline].
Choi WJ, Lee JW. Heterotopic ossification after total ankle arthroplasty. J Bone Joint Surg Br. 2011 Nov. 93(11):1508-12. [Medline].
Klaassen MA, Pietrzak WS. Platelet-rich plasma application and heterotopic bone formation following total hip arthroplasty. J Invest Surg. 2011. 24(6):257-61. [Medline].
Genet F, Ruet A, Almangour W, et al. Beliefs relating to recurrence of heterotopic ossification following excision in patients with spinal cord injury: a review. Spinal Cord. 2015 Feb 17. [Medline].
Strauss JB, Chen SS, Shah AP, et al. Cost of radiotherapy versus NSAID administration for prevention of heterotopic ossification after total hip arthroplasty. Int J Radiat Oncol Biol Phys. 2008 Jan 28. [Epub ahead of print]. [Medline].
Strauss JB, Wysocki RW, Shah A, Chen SS, Shah AP, Abrams RA, et al. Radiation therapy for heterotopic ossification prophylaxis afer high-risk elbow surgery. Am J Orthop (Belle Mead NJ). 2011 Aug. 40(8):400-5. [Medline].
Hoff P, Rakow A, Gaber T, Hahne M, Sentürk U, Strehl C, et al. Preoperative irradiation for the prevention of heterotopic ossification induces local inflammation in humans. Bone. 2013 Apr 6. [Medline].
Sautter-Bihl ML, Liebermeister E, Nanassy A. Radiotherapy as a local treatment option for heterotopic ossifications in patients with spinal cord injury. Spinal Cord. Jan 2000. 38(1):33-6.
Banovac K, Gonzalez F, Renfree KJ. Treatment of heterotopic ossification after spinal cord injury. J Spinal Cord Med. 1997 Jan. 20(1):60-5. [Medline].